Alimera Sciences files $75M IPO

Alimera Sciences is braving a badly roiled public market with plans to push a $75 million IPO. The Atlanta-based biotech is developing ophthalmic drugs. Credit Suisse, Citi, Cowen and Co. and Leerink Swann are underwriting the IPO. Alimera has raised more than $71 million from a group of venture capital groups that include Scale Venture Partners, Domain Associates, Intersouth Partners and Polaris Venture Partners. In addition to developing new therapies, Alimera also markets OTC ophthalmic products. Report